Identification of Specific Components of the Eicosanoid Biosynthetic and Signaling Pathway Involved in Pathological Inflammation during Intra-abdominal Infection with Candida albicans and Staphylococcus aureus
Authors:
- 1 July 2018
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 86 (7)
Abstract
Polymicrobial intra-abdominal infections (IAIs) are a significant cause of morbidity and mortality, particularly when fungal pathogens are involved. Our experimental murine model of IAI involving intraperitoneal inoculation of Candida albicans and Staphylococcus aureus results in synergistic lethality (∼80%) due to exacerbated inflammation. Monomicrobial infection results in no mortality, despite a microbial burden and dissemination similar to those in a coinfection. In the coinfection model, the immunomodulatory eicosanoid prostaglandin E 2 (PGE 2 ) was determined to be necessary and sufficient to induce mortality, implicating PGE 2 as the central mediator of the amplified inflammatory response. The aim of this study was to identify key components of the PGE 2 biosynthetic and signaling pathway involved in the inflammatory response and explore whether these can be targeted to prevent or reduce mortality. Using selective pharmacological inhibitors of cyclooxygenases (COX) or PGE 2 receptor antagonists in the C. albicans - S. aureus IAI mouse model, we found that inhibition of COX and/or blocking of PGE 2 receptor 1 (EP1) or PGE 2 receptor 3 (EP3) signaling reduced proinflammatory cytokine production, promoted interleukin-10 production, reduced cellular damage in the peritoneal cavity, and, most importantly, significantly improved survival. The greatest effect on survival was obtained by the simultaneous inhibition of COX-1 activity and EP1 and EP3 receptor signaling. Importantly, early inhibition of PGE 2 pathways dramatically improved the survival of fluconazole-treated mice compared with that achieved with fluconazole treatment alone. These findings indicate that COX-1 and the EP1 and EP3 receptors mediate the downstream pathological effects of PGE 2 during polymicrobial IAI and may serve as effective therapeutic targets.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01-AI116025)
This publication has 47 references indexed in Scilit:
- Structural features of subtype-selective EP receptor modulatorsDrug Discovery Today, 2017
- Regulation of Interleukin-10 Expression2016
- A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortalityIntensive Care Medicine, 2015
- Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptorsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2015
- Predictors and outcomes of fungal peritonitis in peritoneal dialysis patientsKidney International, 2009
- Comparison between two classes of selective EP3 antagonists and their biological activitiesBioorganic & Medicinal Chemistry Letters, 2006
- Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulationPharmacology & Therapeutics, 2004
- A selective EP4 receptor antagonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E2 in vivo and in vitroBone, 2004
- Molecular mechanisms of diverse actions of prostanoid receptorsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995
- Interleukin-1 receptor antagonist reduces mortality from endotoxin shockNature, 1990